Johnson & Johnson (JNJ) Issues FY18 Earnings Guidance

Johnson & Johnson (NYSE:JNJ) updated its FY18 earnings guidance on Tuesday. The company provided EPS guidance of $8.00-8.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.10. The company issued revenue guidance of $81.0-81.8 billion, compared to the consensus revenue estimate of $81.18 billion.

Several research firms have commented on JNJ. Zacks Investment Research lowered shares of Johnson & Johnson from a buy rating to a hold rating in a report on Monday. Jefferies Group set a $153.00 target price on shares of Johnson & Johnson and gave the company a buy rating in a report on Friday. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $148.00 to $143.00 and set an equal weight rating on the stock in a report on Tuesday, April 10th. Vetr lowered shares of Johnson & Johnson from a hold rating to a sell rating and set a $124.55 price target on the stock. in a report on Thursday, April 5th. Finally, TheStreet lowered shares of Johnson & Johnson from an a rating to a c+ rating in a report on Monday, March 26th. Five research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of $144.03.

How to Become a New Pot Stock Millionaire

NYSE:JNJ opened at $133.15 on Tuesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.12 and a current ratio of 1.41. Johnson & Johnson has a one year low of $120.95 and a one year high of $148.32. The company has a market cap of $350,440.66, a P/E ratio of 18.23, a price-to-earnings-growth ratio of 2.08 and a beta of 0.74.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 17th. The company reported $2.06 EPS for the quarter, topping the consensus estimate of $2.01 by $0.05. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The business had revenue of $20.01 billion for the quarter, compared to the consensus estimate of $19.50 billion. During the same period last year, the company earned $1.83 EPS. The firm’s revenue was up 12.6% compared to the same quarter last year. analysts expect that Johnson & Johnson will post 8.11 earnings per share for the current fiscal year.

In related news, VP Paulus Stoffels sold 155,342 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the sale, the vice president now directly owns 357,906 shares in the company, valued at approximately $46,477,673.16. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.22% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of JNJ. Harding Loevner LP acquired a new position in shares of Johnson & Johnson in the 2nd quarter worth approximately $106,000. IHT Wealth Management LLC lifted its position in shares of Johnson & Johnson by 46.4% in the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after purchasing an additional 3,467 shares during the period. Mountain Capital Investment Advisors Inc acquired a new position in shares of Johnson & Johnson in the 2nd quarter worth approximately $124,000. Financial Gravity Companies Inc. acquired a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $143,000. Finally, Delpha Capital Management LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $166,000. Hedge funds and other institutional investors own 67.23% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Week Herald and is the property of of Week Herald. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://weekherald.com/2018/04/17/johnson-johnson-jnj-issues-fy18-earnings-guidance.html.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply